BioNexus Gene Lab Corp. Announces Pricing Of $5M Public Offering And Uplisting To The Nasdaq Capital Market
Portfolio Pulse from Happy Mohamed
BioNexus Gene Lab Corp. has announced the pricing of its public offering of 1,250,000 shares at $4.00 per share, totaling $5 million. The company has also granted the underwriter an option to purchase up to an additional 187,500 shares. The shares have been approved for listing on the NASDAQ Capital Market under the symbol 'BGLC' and are expected to commence trading on July 20, 2023. The offering is expected to close on July 24, 2023.
July 20, 2023 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioNexus Gene Lab Corp.'s public offering and uplisting to the NASDAQ Capital Market could potentially increase the company's visibility and liquidity, attracting more investors.
The public offering and NASDAQ listing could increase BioNexus' visibility among investors, potentially leading to increased demand for its shares. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100